Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07288515
Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus
Sponsor: AstraZeneca
View on ClinicalTrials.gov
Summary
to address critical gap in knowledge, providing essential data on the real-world effectiveness, safety, associated with acalabrutinib treatment in patients with CLL
Official title: Observational Prospective Study of Acalabrutinib in Chronic Lymphocytic Leukemia Therapy in Real Clinical Practice in Belarus.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
50
Start Date
2025-12-31
Completion Date
2029-12-31
Last Updated
2026-02-23
Healthy Volunteers
No
Conditions
Locations (1)
Research Site
Minsk, Belarus